Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

After acquiring 23andMe, Regeneron Pharmaceuticals has said it will protect user data as it uses DNA data for drug ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Regeneron Pharmaceuticals enters into asset purchase agreement to acquire 23andMe for $256 million: Tarrytown, New York Wednesday, May 21, 2025, 13:00 Hrs [IST] Regeneron Pharmace ...